DSGN
Price
$4.91
Change
-$0.10 (-2.00%)
Updated
Feb 21 closing price
Capitalization
278.01M
12 days until earnings call
LSB
Price
$2.23
Change
-$0.17 (-7.08%)
Updated
Feb 21 closing price
Capitalization
42.55M
Ad is loading...

DSGN vs LSB

Header iconDSGN vs LSB Comparison
Open Charts DSGN vs LSBBanner chart's image
Design Therapeutics
Price$4.91
Change-$0.10 (-2.00%)
Volume$298.19K
Capitalization278.01M
LakeShore Biopharma
Price$2.23
Change-$0.17 (-7.08%)
Volume$12.41K
Capitalization42.55M
DSGN vs LSB Comparison Chart
Loading...
DSGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DSGN vs. LSB commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DSGN is a Hold and LSB is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (DSGN: $4.91 vs. LSB: $2.23)
Brand notoriety: DSGN and LSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DSGN: 172% vs. LSB: 70%
Market capitalization -- DSGN: $278.01M vs. LSB: $42.55M
DSGN [@Biotechnology] is valued at $278.01M. LSB’s [@Biotechnology] market capitalization is $42.55M. The market cap for tickers in the [@Biotechnology] industry ranges from $369.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DSGN’s FA Score shows that 0 FA rating(s) are green whileLSB’s FA Score has 1 green FA rating(s).

  • DSGN’s FA Score: 0 green, 5 red.
  • LSB’s FA Score: 1 green, 4 red.
According to our system of comparison, both DSGN and LSB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DSGN’s TA Score shows that 5 TA indicator(s) are bullish.

  • DSGN’s TA Score: 5 bullish, 3 bearish.

Price Growth

DSGN (@Biotechnology) experienced а +20.34% price change this week, while LSB (@Biotechnology) price change was -8.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

DSGN is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DSGN($278M) has a higher market cap than LSB($42.6M). DSGN YTD gains are higher at: -20.421 vs. LSB (-35.549). DSGN has higher annual earnings (EBITDA): -60.23M vs. LSB (-220.1M). DSGN has more cash in the bank: 254M vs. LSB (49.5M). DSGN has less debt than LSB: DSGN (2.52M) vs LSB (369M). LSB has higher revenues than DSGN: LSB (672M) vs DSGN (0).
DSGNLSBDSGN / LSB
Capitalization278M42.6M653%
EBITDA-60.23M-220.1M27%
Gain YTD-20.421-35.54957%
P/E RatioN/AN/A-
Revenue0672M-
Total Cash254M49.5M513%
Total Debt2.52M369M1%
TECHNICAL ANALYSIS
Technical Analysis
DSGN
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
87%
Declines
ODDS (%)
Bearish Trend 11 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
76%
View a ticker or compare two or three
Ad is loading...
DSGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TWCIX125.59N/A
N/A
American Century Select Inv
WLIVX15.83N/A
N/A
WCM Focused International Equity Inv
MMFYX16.68N/A
N/A
MassMutual Equity Opports Svc
EACPX60.26N/A
N/A
Eaton Vance Tax-Managed Multi-Cap Gr A
IUERX25.48-0.14
-0.55%
JPMorgan International Focus R2

DSGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DSGN has been loosely correlated with MDGL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if DSGN jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DSGN
1D Price
Change %
DSGN100%
-2.00%
MDGL - DSGN
38%
Loosely correlated
-4.22%
TRDA - DSGN
37%
Loosely correlated
-0.23%
RCKT - DSGN
36%
Loosely correlated
-3.68%
AGIO - DSGN
36%
Loosely correlated
+4.36%
EDIT - DSGN
35%
Loosely correlated
-6.80%
More

LSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, LSB has been loosely correlated with STTK. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if LSB jumps, then STTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LSB
1D Price
Change %
LSB100%
-6.91%
STTK - LSB
38%
Loosely correlated
+6.20%
BCTX - LSB
30%
Poorly correlated
-12.82%
GLTO - LSB
24%
Poorly correlated
-6.82%
GNFT - LSB
23%
Poorly correlated
-2.30%
DSGN - LSB
21%
Poorly correlated
-2.00%
More